Literature DB >> 11181843

Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter.

R E Whitehead1, J V Ferrer, J A Javitch, J B Justice.   

Abstract

There is evidence to suggest that dopamine (DA) oxidizes to form dopamine ortho-quinone (DAQ), which binds covalently to nucleophilic sulfhydryl groups on protein cysteinyl residues. This reaction has been shown to inhibit dopamine uptake, as well as other biological processes. We have identified specific cysteine residues in the human dopamine transporter (hDAT) that are modified by this electron-deficient substrate analog. DAQ reactivity was inferred from its effects on the binding of [(3)H]2-beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (beta-CFT) to hDAT cysteine mutant constructs. One construct, X5C, had four cysteines mutated to alanine and one to phenylalanine (Cys(90)A, Cys(135)A, C306A, C319F and Cys(342)A). In membrane preparations 1 mM DAQ did not affect [(3)H]beta-CFT binding to X5C hDAT, in contrast to its effect in wild-type hDAT in which it reduced the B:(max) value by more than half. Wild-type cysteines were substituted back into X5C, one at a time, and the ability of DAQ to inhibit [(3)H]beta-CFT binding was assessed. Reactivity of DAQ with Cys(90) increased the affinity of [(3)H]beta-CFT for the transporter, whereas reactivity with Cys(135) decreased the affinity of [(3)H]beta-CFT. DAQ did not change the K:(D) for [(3)H]beta-CFT binding to wild-type. The reactivity of DAQ at Cys(342) decreased B:(max) to the same degree as wild-type. The latter result suggests that Cys(342) is the wild-type residue most responsible for DAQ-induced inhibition of [(3)H]beta-CFT binding.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181843     DOI: 10.1046/j.1471-4159.2001.00125.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  48 in total

1.  Nitric oxide inhibits uptake of dopamine and N-methyl-4-phenylpyridinium (MPP+) but not release of MPP+ in rat C6 glioma cells expressing human dopamine transporter.

Authors:  Bo-Jin Cao; Maarten E A Reith
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 2.  Neurotoxins as Preclinical Models for Parkinson's Disease.

Authors:  Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2018-01-08       Impact factor: 3.911

Review 3.  Aminochrome as a preclinical experimental model to study degeneration of dopaminergic neurons in Parkinson's disease.

Authors:  Irmgard Paris; Sergio Cardenas; Jorge Lozano; Carolina Perez-Pastene; Rebecca Graumann; Alejandra Riveros; Pablo Caviedes; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2007-09       Impact factor: 3.911

Review 4.  Neurodegeneration and neuroprotection in Parkinson disease.

Authors:  Stanley Fahn; David Sulzer
Journal:  NeuroRx       Date:  2004-01

5.  L-DOPA-quinone Mediated Recovery from GIRK Channel Firing Inhibition in Dopaminergic Neurons.

Authors:  Bruno M Bizzarri; Lorenzo Botta; Daniela Aversa; Nicola B Mercuri; Giulio Poli; Alessandro Barbieri; Nicola Berretta; Raffaele Saladino
Journal:  ACS Med Chem Lett       Date:  2019-01-09       Impact factor: 4.345

6.  Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-01-29       Impact factor: 3.911

7.  Dopamine induces supernumerary centrosomes and subsequent cell death through Cdk2 up-regulation in dopaminergic neuronal cells.

Authors:  Francisco J Diaz-Corrales; Masato Asanuma; Ikuko Miyazaki; Ko Miyoshi; Nobutaka Hattori; Norio Ogawa
Journal:  Neurotox Res       Date:  2008-12       Impact factor: 3.911

Review 8.  Nucleus accumbens invulnerability to methamphetamine neurotoxicity.

Authors:  Donald M Kuhn; Mariana Angoa-Pérez; David M Thomas
Journal:  ILAR J       Date:  2011

9.  Dopamine disposition in the presynaptic process regulates the severity of methamphetamine-induced neurotoxicity.

Authors:  Donald M Kuhn; Dina M Francescutti-Verbeem; David M Thomas
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 10.  Modulation of alpha-synuclein aggregation by dopamine: a review.

Authors:  Su Ling Leong; Roberto Cappai; Kevin Jeffrey Barnham; Chi Le Lan Pham
Journal:  Neurochem Res       Date:  2009-05-15       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.